NA
CPIX icon

NewEdge Advisors’s Cumberland Pharmaceuticals CPIX Stock Holding History

NewEdge Advisors’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,203
Closed -$4.79K – 4194
2025
Q4 		$4.79K Buy
1,203
+447
+59% +$1.32K ﹤0.01% 3694
2025
Q3 		$2.36K Sell
756
-672
-47% -$2.23K ﹤0.01% 3745
2025
Q2 		$4.78K Buy
+1,428
New +$6.76K ﹤0.01% 3424

Other funds holding CPIX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

NewEdge Advisors's CPIX Position: Q1 2026 in Review

NewEdge Advisors sold out of Cumberland Pharmaceuticals (CPIX) in Q1 2026, closing a stake of 1,203 shares — an estimated $4.79K sold.

NewEdge Advisors first reported a position in CPIX in Q2 2025 and held it in 3 quarters. The position peaked at $4.79K in Q4 2025. 29 funds tracked by Wall St. Rank hold CPIX as of Q1 2026.

  • NewEdge Advisors reported no remaining Cumberland Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 1,203 Cumberland Pharmaceuticals shares in Q1 2026, an estimated $4.79K.
  • NewEdge Advisors first reported a position in Cumberland Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • NewEdge Advisors's Cumberland Pharmaceuticals position peaked at $4.79K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.